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ABSTRAK
Latar belakang: prevalensi Hepatitis B di Indonesia masih tinggi dan pengobatan dengan obat antivirus 
memerlukan pamantauan untuk menilai respons terapi. Salah satu metode pemantauan respons terapi yang 
non-infasif dan mudah dilakukan di Indonesia adalah dengan pengukuran derajat kekerasan hati atau transient 
elatography (TE)dan alanine aminotransferase-to-platelet ratio index (APRI) yang merupakan metode alternatif 
untuk mendeteksi fibrosis hati. Meskipun demikian, akurasinya dalam mengevaluasi respon terapi pada pasien 
hepatitis B kronik di Indonesia masih belum diketahui. Penelitian ini bertujuan untuk mengetahui perubahan 
derajat kekerasan hati dengan menggunakan transient elastography (TE) dan APRI sebelum dan setelah terapi 
antiviral per oral selama satu tahun pada pasien hepatitis B kronik dan korelasi antara TE dan APRI. Metode: 
desain penelitian yang digunakan adalah studi kohort retrospektif pada pasien hepatitis B kronik di Rumah Sakit 
Cipto Mangunkusumo Jakarta yang diberikan terapi selama bulan Januari 2012 hingga Desember 2014. Pasien 
diberikan antiviral dengan analog nukleosida terbaru (entecavir atau telbivudine) selama minimal satu tahun. 
TE dan APRI diperiksakan sebelum dan setelah terapi. Reduksi TE dan APRI diuji secara statistik menggunakan 
korelasi Spearman. Hasil: penelitian ini mengikutsertakan 41 pasien dan mendapatkan nilai median kekerasan hati 
berkurang secara signifikan dari 10,8 menjadi 5,9 kPa setelah terapi antiviral per oral (p<0,001, Uji Wilcoxon). 
Nilai median APRI juga berkurang secara signifikan dari 1,13 menjadi 0,43 setelah terapi (p<0,001, Uji Wilcoxon). 
Sebelum terapi dimulai nilai korelasi antara derajat kekerasan hati dan APRI menunjukkan hasil 0.40 dan nilai 
korelasi setelah terapi antiviral menjadi 0,73. Kesimpulan: derajat kekerasan hati yang diukur menggunakan TE 
dan APRI berkurang secara signifikan setelah terapi antiviral selama satu tahun pada pasien hepatitis B kronik.
Terdapat korelasi yang signifikan antara TE dan APRI.
Kata kunci: terapi antiviral, indeks aspartate aminotransferase-to-platelet ratio(APRI), hepatitis B kronik, 
derajat kekerasan hati, transient elastography.
ABSTRACT
Background: Hepatitis B is endemic in Indonesia and treatment response need to be monitored during 
and after antiviral therapy. Liver stiffness measurement and alanine aminotransferase-to-platelet ratio index 
(APRI) are noninvasive method to detect liver fibrosis available in Indonesia. However, little is known about 
their ability to evaluate treatment response in chronic hepatitis B (CHB) patients in Indonesia. This study 
aimed to investigate liver stiffness changes by transient elastography (TE) and APRI before and after one-
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year oral antiviral treatment in CHB patients and the correlation between TE and APRI. Methods: this study 
was retrospective cohort on CHB patients in CiptoMangunkusumo Hospital, Jakarta who uderwent treatment 
between January 2012 and December 2014. Patients received oral antiviral treatment with newer nucleoside 
analogues (entecavir or telbivudine) for at least one year. TE and APRI were obtained before and after treatment. 
TE and APRI reductions were analyzed statistically with Spearman’s test. Results: a total of 41 patients were 
enrolled in this study. Median liver stiffness value was significantly reduced from 10.8 to 5.9 kPa after oral 
antiviral treatment (p<0.001, Wilcoxon’s test). Median APRI was also significantly reduced from 1.13 to 0.43 
after treatment (p<0.001, Wilcoxon’s test). The correlation between liver stiffness and APRI before treatment 
was weak (r=0.40), but it was strong after treatment (r=0.73). Conclusion: the liver stiffness measured with 
transient elastography and APRI significantly decreased after one year of antiviral treatment in chronic HBV 
patients. There was a significant correlation between TE and APRI after one year of treatment.
Keywords: antiviral therapy, aspartate aminotransferase-to-platelet ratio index (APRI), chronic hepatitis 
B, liver stiffness measurement, transient elastography.
INTRODUCTION
Hepatitis B infection is a public health 
problem in Indonesia. Based on the National 
Basic Health Research 2007, the prevalence of 
HBsAg-positive case was 9.7% in men and 9.3% 
in women. The highest prevalence was found 
among 45-49 years age group (11.9%).1 Hepatitis 
B virus (HBV) is responsible for various medical 
conditions from asymptomatic carriers to 
cirrhosis and hepatocellular carcinoma. It is the 
cause of 500.000 to 1.2 million deaths annually, 
which is related to cirrhosis and hepatocellular 
carcinoma.2 Obviously, antiviral treatment and 
prevention of disease progression is the main 
goal of chronic hepatitis B (CHB) management.
Patients treated with oral antiviral therapy 
should be regularly monitored. The current 
practice of treatment monitoring is done by 
measuring serum liver enzymes, HBV-DNA and 
serological markers such as hepatitis B e antigen 
(HBeAg), hepatitis b surface antigen (HBsAg), 
and anti-HBs.3 The Asian-Pacific Association for 
the Study of the Liver (APASL) 2012 guidelines 
recommended to start evaluation using viral 
seromarkers at 3 months after treatment and 
should be repeated every 3 months during 
treatment.4 The guidelines also recommended 
assessing fibrosis stage before treatment either 
invasively with liver biopsy or non-invasively.5
Transient elastography (TE) is one of the 
most widely used non-invasive methods to assess 
liver fibrosis.6 Initial TE studies were done on 
Caucasian chronic hepatitis C patients.7,8 Other 
studies on TE have also been done in alcoholic 
fatty liver disease,9 primary biliary cirrhosis10 
and hepatitis B.11,12
Combination of biochemical markers is 
another alternative to assess liver fibrosis in CHB 
patients.13 One of the most economical methods 
is by calculating the aspartate aminotransferase 
(AST)-to-platelet-ratio index (APRI).14 Liver 
fibrosis stage and APRI is significantly correlated 
in CHB patients.15 Theoretically, platelet count 
is reduced when fibrosis stage increases. This 
is caused by increased portal hypertension in 
advanced fibrosis thereby increasing platelet 
sequestration and its destruction in the enlarged 
spleen.16
A cross-sectional study in Jakarta has shown 
that liver stiffness tend to increase parallel to 
fibrosis stage. The median of liver stiffness in F0-
F1, F2, F3, and F4 were 5.45, 5.8, 7.8, and 29.3 
kPa, respectively. The APRI also tends to increase 
when the fibrosis stage increases.17 Both TE and 
APRI has good diagnostic accuracy to detect 
significant liver fibrosis (>F2) in CHB patients.17
Study on CHB patients has shown that 
long-term antiviral treatment might improve 
liver histology and produce liver fibrosis 
regression.18-20 Treatment response monitoring 
with TE showed that entecavir treatment for at 
least 12 months may reduce liver stiffness from 
11.2 kPa to 7.8 kPa.21 Non-invasive methods 
like TE and APRI has not been well studied in 
Indonesia to monitor treatment response of CHB 
patients. Therefore, this study was aimed to know 
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the alterations of liver stiffness using TE and 
APRI after oral antiviral treatment for at least 
one year in CHB patients.
METHODS
This was a cohort retrospective study 
conducted at Cipto Mangunkusumo Hospital 
(CMH), Jakarta between January and June 2013.
The study was cohort retrospective  using data of 
CHB patients who had been diagnosed and treated 
in CMH before 2013 and were followed-up during 
the study period. Patients were included when they 
had a record of liver stiffness measurement with 
TE, had complete initial laboratory data (blood 
chemistry and liver function test) and had been 
treated with oral antiviral for at least one year. 
The minimum number of subjects was calculated 
using the analytical numeric formula for paired 
subjects with 5% type I error and 80% research 
power. The standard deviation of liver stiffness 
difference between before and after treatment 
was estimated at twice of the minimum mean 
difference (2 kPa) or equal to 4 kPa. Therefore, 
the minimum sample size needed was 31 patients. 
Patients were excluded when there was a co-
infection with hepatitis C virus (HCV) or human 
immunodeficiency virus (HIV), failure of TE 
readings, and hepatocellular carcinoma.
Liver Stiffness Measurement
Liver stiffness was measured by using transient 
elastography (TE) machine (FibroScan®, 
Echosens, Paris, France) according to the 
instructions provided by the manufacturer.22 It is 
equipped with a probe that includes a ultrasound 
(US) transducer mounted on a vibrator.
The measurement depth was between 25 
and 65 mm. Measurement was considered valid 
if 10 successful acquisitions were obtained with 
success rate (SR) of at least 60% and the ratio 
of interquartile range over median (IQR/M) was 
30% less.23 Results were expressed in kilopascals 
(kPa).TE was considered normal if liver stiffness 
was 5.0 kPa or lower. In patients with normal 
ALT levels, fibrosis stage measured by TE was 
categorized as: F1 (>5-6 kPa), F2 (>6-9 kPa), 
F3 (>9-12 kPa), F4 (>12 kPa). In patients with 
elevated ALT levels, fibrosis was staged as 
follows: F1 (>5-7.5 kPa0), F2 (>7.5-12 kPa), F3 
(>12-13.4 kPa), and F4 (>13.4 kPa).12
Calculation of APRI
APRI was calculated twice, before and after 
oral antiviral therapy. APRI was calculated as 
[(AST/ ASTULN) x100] / platelet count (109/ 
L). ASTULN is the upper limit of the normal 
AST value, which were 35 IU/mL in women and 
50 IU/mL in men. The cut-off value of APRI to 
detect significant liver fibrosis was set to 0.5.24 
Liver Biopsy
Liver biopsy was done percutaneously under 
local anesthesia. A specimen was adequate when 
it at least contained six portal tracts and measured 
1.5 cm in length. Specimens were fixed in 4% 
buffered formalin and embedded in paraffin. 
Specimens were cut in 4-μm thickness and were 
stained with haematoxyllin eosin and Masson’s 
trichrome staining.
Fibrosis stage was evaluated using METAVIR 
scoring system as follows: F0 indicated no 
fibrosis; F1, portal fibrosis without septa; F2, 
portal fibrosis with a few septa; F3, numerous 
septa without cirrhosis; and F4, cirrhosis.25 
Significant fibrosis was defined as F2 or more.
Data Management and Statistic Analysis
Characteristics of the study subjects were 
presented descriptively. The difference of liver 
stiffness and APRI before and after treatment was 
assessed using the Wilcoxon test (for skewed 
data). A p value of less than 0.05 was considered 
significant. Correlation between TE and APRI 
was expressed as Spearman’s coefficient of 
correlation (r). A correlation was considered 
weak if r< 0.5, moderate if r = 0.5-0.7 and strong 
if r>0.7 Analysis was done with the SPSS version 
17 (SPSS Inc., Chicago, Illinois, USA).
Patients signed a written informed consent 
before involvement in the study. Ethical approval 
was obtained from the Ethical Committee 
for Medical Research, Faculty of Medicine, 
University of Indonesia. No 05/H2.F1/ETIK/ 
2013 dated January 7th, 2013.
RESULTS
A total of 41 CHB patients were enrolled. 
More than two-thirds of them were men. The 
median age was 50 years old. Twenty-three 
patients were HBeAg-positive and had high 
serum HBV-DNA levels (Table 1). The mean 
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period of antiviral treatment was 18.1 (4.1) 
months.
Evaluation of Treatment Response
The median of initial liver stiffness was 10.8, 
ranging from 4.1 to 61.5 kPa. It was significantly 
reduced after treatment (p<0.001). Median 
APRI was reduced from 1.13 (range, 0.20 – 
21.13) at baseline to 0.43 (range, 0.12-2.00) 
after treatment (p<0.001). Reduction of TE and 
APRI was similar between HBeAg-positive and 
HBeAg-negative patients (Figure 1A and 1B). 
There was a moderate correlation between initial 
TE and APRI (r=0.40, Spearman’s correlation 
test). After oral antiviral treatment, there was a 
strong correlation between TE and APRI (r=0.73; 
Spearman’s correlation test).
Evaluation of liver fibrosis stage using TE 
showed that liver stiffness reduction could be 
reasonably translated into fibrosis stage. None of 
patients with initial liver histopathology showing 
F2 and F3 fibrosis underwent disease progression. 
On the contrary, improvement occurred in 7/8 
(87.5%) of F2 patients, 7/8 (87.5%) of F3 patients, 
and 13/17 (76.5%) of F4 patients (Table 4).
DISCUSSION
Treatment monitoring with TE or APRI has 
not been routinely done in Indonesia. However, 
guidelines on CHB management have included 
Table 1. Characteristics of the study subjects (n=41)
Variables Value
Male gender, n (%) 29 (70.7)
Age (years), median (range) 50 (22-67)
Platelet count (x109/μL), mean (SD) 194.4 (71.3)
AST (U/L), median (range) 52 (18–530)
ALT (U/L), median (range) 49 (16-850)
 - Normal ALT, n (%) 10 (24.4)
 - ALT 1-2xULN, n (%) 12 (29.3)
 - ALT >2xULN, n (%) 19 (46.3)
HBeAg-positive, n (%) 23 (56.1)
HBV-DNA (log copies/mL), mean (SD) 5.5 (2.1)
Table 2. The association between liver fibrosis proven by biopsy and non-invasive measures of fibrosis stage
Fibrosis stage by
Fibrosis stage based on histopathology
p value*
F0-F1 - n (%) F2-F4 - n (%)
TE
F0-F1 5 (62.5) 7 (21.2) 0.034
F2-F4 3 (37.5) 26 (28.8)
APRI
F0-F1 (<0.5) 6 (75.0) 7 (21.2) 0.007
F2-F4 (>0.5) 2 (26.0) 26 (78.8)
* Fisher exact test; p value <0.05 was considered statistically significant
Table 3. Concordance of fibrosis stage by histopathology assessment and transient elastography (n=41)
Fibrosis stage by TE*
Fibrosis stage by histopathology (n, %)
F0 F1 F2 F3 F4
F0 (< 5 kPa) 0 1 (12.5) 2 (25.0) 0 0
F1 (>5-6 or >5-7.5 kPa) 0 4 (50.0) 5 (62.5) 0 0
F2 (>6-9 or >7.5-12 kPa) 0 3 (37.5) 1 (12.5) 4 (50.0) 1 (5.9)
F3 (>9-12 or >12-13.4 kPa) 0 0 0 3 (37.5) 2 (11.8)
F4 (>12 or >13.4 kPa) 0 0 0 1 (12.5) 14 (82.4)
Initial Liver Fibrosis Evaluation
Based on liver stiffness measurement 
algorithm, significant liver fibrosis was correctly 
detected in 26 (78.8%) patients. Using a cut-off 
value of 0.5 for significant fibrosis, APRI could 
correctly identifymost patients with F2-F4 
(Table 2).When analyzed further, fibrosis stage 
assessment by TE can correctly classified F0-
F1 patients and F3-F4 patients, but not the F2 
category (Table 3).
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histological response in addition to virological 
and biochemical responses. Evaluation of liver 
fibrosis may be done invasively by biopsy or 
non-invasively.26
Our study showed that liver stiffness was 
reduced after treatment which may indicate 
histological improvement. Assessment of liver 
fibrosis in CHB patients should be based on 
ALT levels. Using the ALT-based algorithm, TE 
A B
Figure 1. (A) Reduced liver stiffness after oral antiviral therapy in chronic hepatitis B patients. (B) Reduced APRI after oral 
antiviral therapy in chronic hepatitis B patients (n=41)
Table 4. Liver fibrosis improvement by transient elastography assessment after oral antiviral therapy in chronic hepatitis 
B patients (n=41)
Fibrosis stage after treatment by TE*
Initial fibrosis stage by histopathology, n (%)
F1 F2 F3 F4
F0 (<5 kPa) 5 (62.5) 3 (37.5) 2 (25.0) 3 (17.63)
F1 (>5-6 or >5-7.5 kPa) 2 (25.0) 4 (50.0) 1 (12.5) 1 (5.9)
F2 (>6-9 or >7.5-12 kPa) 1 (12.5) 1 (12.5) 4 (50.0) 3 (17.6)
F3 (>9-12 or >12-13.4 kPa) 0 0 1 (12.5) 6 (35.4)
F4 (>12 or >13.4 kPa) 0 0 0 4 (23.5)
*liver stiffness measurement was categorized based on ALT normal vs. 1-5x ULN12
Table 5. Liver fibrosis improvement after oral antiviral 
therapy in chronic hepatitis B patients (n=41)
Fibrosis stage
Fibrosis stage based on 
histopathology
F0-F1, n (%) F2-F4, n (%)
TE
F0-F1 7 (87.5) 29 (87.9)
F2-F4 1 (12.5) 4 (12.1)
APRI
F0-F1 (<0.5) 6 (75.0) 18 (54.5)
F2-F4 (>0.5) 2 (26.0) 15 (45.5)
could detect advanced fibrosis more accurately 
than fibrosis stage F2. This category has been 
regarded as gray zone with TE values between 
6 and 9 kPa (or 7.5 to 9 kPA in elevated ALT) 
which need liver biopsy for confirmation.13 
Research on TE to show fibrosis regression had 
been shown in other studies.21,27 TE could also 
be used to evaluate disease progression. A study 
reported that untreated patients had increased 
liver stiffness from 6.1 to 6.3 kPa with mean 
observation period of 422 (358-709) days.28
Liver stiffness has been known to increase 
when there was active inflammation such as 
acute flare with ALT elevation. In this case, 
liver stiffness may be 1.5 times higher than its 
value when the ALT levels return to normal.29 
Nevertheless, TE has a good reproducibility to 
be used in daily practice. The inter- and intra-
examiner variation ranges from 3.2 to 3.3%. Other 
study found high correlation between to examiners 
(r=0.98).30 However, reliability decrease in lower 
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fibrosis stage (F0-F1) compared to higher fibrosis 
stage (>F2). Measurement reliability is also 
reduced when hepatic steatosis is present in more 
than 25% of liver tissue and if body mass index is 
25 kg/m2 or more.29
In this study, median APRI was reduced 
significantly after antiviral treatment. APRI was 
initially used in chronic hepatitis C patients to 
predict significant fibrosis and cirrhosis.31 Other 
study involving both chronic hepatitis C and B 
with negative HBeAg showed that APRI was 
significantly associated with fibrosis stage.32
The reported APRI cut-off level for 
significant fibrosis is 0.76 (95%CI 0.74-0.79) 
in CHC patients.33 In CHB patients, two studies 
reported that APRI’s AUC for significant fibrosis 
were 0.63 and 0.72.20,34 Previous study in Jakarta 
found a much lower cut-off (0.22) for significant 
liver fibrosis; however, that study only includes 
4 patients with cirrhosis that may have skewed 
the distribution of APRI values.21 A recent study 
suggested an APRI value of 0.5 in detecting 
significant fibrosis in CHB patients which had 
87.7% sensitivity and 90.8% specificity.35
TE and APRI have a similar accuracy 
in detecting liver fibrosis in CHB patients. 
However, the cost of performing TE is much 
higher than APRI. Therefore, APRI should be 
used in primary care when TE facility is not 
available.21
This study has several limitations. Firstly, 
the study subjects were not pre-selected based 
on their ALT levels. Some patients had ALT 
levels more than 5 times the ULN when TE was 
performed thereby it might cause higher liver 
stiffness measurement. Secondly, liver fibrosis 
stage after treatment was not confirmed by 
histopathological assessment.
CONCLUSION
This study showed that liver stiffness 
measured by transient elastography (TE) 
and aspartate-to-platelet ratio index (APRI) 
significantly reduce after 12-month oral antiviral 
treatment in chronic hepatitis B patients. Liver 
stiffness was strongly correlated with APRI in 
these patients. Both TE and APRI are potentially 
used for treatment monitoring in CHB patients 
receiving oral antiviral therapy.
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